Nutriband Subsidiary Active Intelligence to Showcase Wellness Products at ECRM Conference

Nutriband Inc. (NASDAQ: NTRB) announced that its wholly owned subsidiary, Active Intelligence, will participate in the June 2026 ECRM conference, where it plans to showcase its expanding portfolio of wellness, recovery and performance-focused consumer products to buyers from major retail, pharmacy and healthcare organizations. The company will feature its existing AI Tape line and introduce new products including AI Performance Tape, AI Energy Patches and AI Sleep as it seeks to expand retail partnerships and distribution opportunities. This move signals Nutriband's strategic diversification into the consumer wellness market, leveraging its expertise in transdermal technology.

The ECRM conference provides a platform for Active Intelligence to connect with key decision-makers from leading retailers and healthcare entities, potentially accelerating the adoption of its products. The company's AI Tape line, already established in the market, offers a foundation for the new offerings. AI Performance Tape targets athletes and active individuals, while AI Energy Patches and AI Sleep address energy and sleep support, respectively. These products align with growing consumer demand for non-invasive, transdermal delivery systems for wellness and performance enhancement.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. The company's expansion into consumer wellness through Active Intelligence represents a strategic pivot to capture a broader market. The success of this initiative could provide additional revenue streams and reduce reliance on pharmaceutical development timelines, which are often lengthy and uncertain.

The announcement comes as the wellness industry continues to expand, with consumers increasingly seeking convenient and effective health solutions. Active Intelligence's products, delivered via transdermal patches, offer a unique value proposition by avoiding oral ingestion and providing controlled release. If the company secures retail partnerships at the ECRM conference, it could significantly boost its market presence and brand recognition among consumers.

Investors and industry observers will be watching for updates on partnerships and product launches following the conference. For more information, visit the company’s newsroom at https://ibn.fm/NTRB. The full press release is available at https://ibn.fm/sZ1zJ.